Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Botanical or Opioid or [[:Category:SGLT2_inhibitors|SGLT2 inhibitor]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (32) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Farxiga (US), Forxiga (international) (1) · Heroin (1) · Jardiance (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)
uses:
None (49) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) · '"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1)
starting dose:
None (49) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (49) · 10 mg, 25 mg tablets (1) · 5 mg, 10 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (49) · 10 mg/d (1) · 25 mg/d (1) · 360 mg/day (1)
routes:
None (49) · Oral (2) · PO (only formulation marketed in the US). (1)
onset:
None (49) · 30–60 min (PO) (1) · Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1)
duration:
None (49) · 24 hours (2) · 4–6 hours (1)
halflife:
None (49) · 2.5–3 hours (1) · ~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1)
bioavailability:
None (49) · High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1)
pregnancy:
None (49) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
legal:
None (49) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 55 results in range #1 to #55.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"